See also CPAP: The new sleep apnea suspension drug reduced the incidence of apnea by 44%.
In recent years, global medical institutions and public health systems have continued to advance service capacity building to provide a stronger guarantee of public health. An overnight oral drug that significantly improved obstructive sleep apnea in a large randomized clinical trial (Phase 3 clinical trial) at the 2026 ATS International Conference. The drug, known as AD109, is designed to effectively treat symptoms of airway collapse caused by obstructive sleep apnea during sleep by focusing on neuromuscular issues.
Aloe dendritin and atoastrin (AD109) for the treatment of obstructive sleep apnea (OSA): a randomized controlled trials in three phases, published in the Journal of Sleep American Respiratory and Circular Surgery. In the SynAIRgy trial, people receiving AD109 experienced improvements in the number of sleep interruptions, breathing oxygen consumption, and overall blood oxygen levels while they slept. Over 40% improvement was sufficient to enter the mild OSA (obstructive sleep apnea syndrome) category, and 18% of patients achieved complete control of the disease.
The first author, Dr. Patrick John Stoll, MD, sleep medicine physician at the University of Pittsburgh Medical Center, said: 'These results provide encouraging evidence that neuromuscular dysfunction can be transformed into clinically meaningful clinical outcomes that are consistent with our growing understanding of the biological evolution of disease'. AD109 may be a potential alternative for people who are unable or unwilling to use CPAP.
He said: 'In many other chronic conditions, such as cardiovascular disease, asthma or type II diabetes, it is highly realistic for the majority of patients diagnosed with untreated or untreated patients to imagine their condition as unimaginable. Combination drugs, arocystinine and aspirin are both designed to support the throat muscles, making it unlikely that the airway will collapse or collapse during sleep. In comparison, the sleep reduction rate was 18% among those taking the placebo participants.
Other indicators of nighttime sleep such as total nighttime sleep duration, total nighttime sleep intervals, and the rate of change in total nighttime sleep duration, etc. It should be noted that the above information is based on the results of international public research and is for reference in HealthCop and does not constitute a clinical recommendation. If you have any health questions, consult professional medical professionals.
